Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK_Final
Zhaoke Ophthalmology is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise while designing the pipeline, the Company has initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DM...
United States Hong Kong Li Xiaoyi Goldman Sachs Asia Matthews International Capital Management Golden Valley Global
Source: dgap.de